Overview

• Vaxart's experimental oral norovirus vaccine demonstrated robust antibody and T-cell responses in adults aged 55-80, comparable to younger populations previously studied.
• The vaccine induced significant mucosal immunity, with antibody increases observed in saliva, nasal cavities, and the gastrointestinal tract, suggesting potential protection against respiratory viruses.
• Participants in the Phase 1b trial experienced an 85% reduction in viral shedding, indicating potential to limit virus transmission even in breakthrough infections.
• The vaccine was well-tolerated, with mild to moderate side effects such as headache and fatigue reported at rates similar to the placebo group.
• Vaxart is advancing second-generation vaccine candidates with improved immunogenicity, with clinical trial data expected by mid-2025.